1	Dynamics of SARS-CoV-2 exposure in Malawian blood donors: a retrospective						
2	seroprevalence analysis between January 2020 and February 2021						
3	Mandolo J <sup>1</sup> , Msefula J <sup>1</sup> , Henrion MYR <sup>1,2</sup> , Brown C <sup>1</sup> , Moyo B <sup>1</sup> , Samon A <sup>3</sup> , Moyo-Gwete T <sup>4,5</sup> ,						
4	Makhado Z <sup>4,5</sup> , Ayres F <sup>4,5</sup> , Motlou T <sup>4,5</sup> , Mzindle N <sup>4,5</sup> , Kalata N <sup>1</sup> , Muula AS <sup>6</sup> , Kwatra G <sup>7,8,9</sup> ,						
5	Msamala N <sup>3</sup> , Likaka A <sup>3</sup> , Mfune T <sup>3</sup> , Moore PL <sup>4,5</sup> , Mbaya B <sup>3</sup> , French N <sup>10</sup> , Heyderman RS <sup>11</sup> ,						
6	Swarthout TD <sup>1,11¶</sup> , Jambo KC <sup>1,2¶*</sup>						
7							
8	1. Malawi-Liverpool-Wellcome Trust Clinical Research programme, Blantyre, Malawi						
9	2. Liverpool School of Tropical Medicine, Liverpool, United Kingdom						
10	3. Malawi Blood Transfusion Services, Blantyre, Malawi						
11	4. National Institute for Communicable Diseases of the National Health Laboratory						
12	Services, South Africa						
13	5. MRC Antibody Research Unit, School of Pathology, University of the Witwatersrand,						
14	South Africa						
15	6. Kamuzu University of Health Sciences, Blantyre, Malawi						
16	7. Respiratory and Meningeal Pathogens Research Unit, South Africa						
17	8. Department of Science/ National Research Foundation: Vaccine Preventable Diseases,						
18	University of the Witwatersrand, Faculty of Health Science, Johannesburg, South Africa.						
19	9. Department of Clinical Microbiology, Christian Medical College, Vellore, India.						
20	10. University of Liverpool, Liverpool, United Kingdom						
21	11. NIHR Global Health Research Unit on Mucosal Pathogens, Research Department of						
22	Infection, Division of Infection and Immunity, University College London, London, UK						
23							
24	*Corresponding author						
25	Email: Kondwani.Jambo@lstmed.ac.uk or kjambo@mlw.mw (KCJ)						
26							
27	<sup> </sup>						
28	<sup>¶</sup> Joint senior authors						
29							
30	Main text: 3488 words						
31							
32	Rufning rittle: SARS-COV-2 antiDodies in Malawian Diodo donors						

# 33 Abstract

34 Background: As at end of July 2021, the COVID-19 pandemic has been less severe in sub-35 Saharan Africa than elsewhere. In Malawi, there have been two subsequent epidemic 36 waves. We therefore aimed to describe the dynamics of SARS-CoV-2 exposure in Malawi. 37 **Methods:** We measured the seroprevalence of anti-SARS-CoV-2 antibodies among randomly 38 selected blood donor sera in Malawi from January 2020 to February 2021. In a subset, we 39 also assesed in vitro neutralisation against the original variant (D614G WT) and the Beta 40 variant. 41 Findings: A total of 3586 samples were selected from the blood donor database, of which 42 2685 (74.9%) were male and 3132 (87.3%) were aged 20-49 years. Of the total, 469 (13.1%) 43 were seropositive. Seropositivity was highest in October 2020 (15.7%) and February 2021 44 (49.7%) reflecting the two epidemic waves. Unlike the first wave, both urban and rural areas 45 had high seropositivity by February 2021, Balaka (rural, 37.5%), Blantyre (urban, 54.8%), 46 Lilongwe (urban, 54.5%) and Mzuzu (urban, 57.5%). First wave sera showed potent in vitro 47 neutralisation activity against the original variant (78%[7/9]) but not the Beta variant (22% 48 [2/9]). Second wave sera potently neutralised the Beta variant (73% [8/11]). 49 Interpretation: The findings confirm extensive SARS-CoV-2 exposure in Malawi over two 50 epidemic waves with likely poor cross-protection to reinfection from the first on the second 51 wave. Since prior exposure augments COVID-19 vaccine immunity, prioritising 52 administration of the first dose in high SARS-CoV-2 exposure settings could maximise the 53 benefit of the limited available vaccines in Malawi and the region. 54 55 Word count: 247 words 56 57 58 59 60 61 62 63

# 64 **Research in context**

# 65 Evidence before this study

- 66 We searched PubMed on August 16, 2021, with no language restrictions, for titles and
- 67 abstracts published between Jan 1, 2020, and August 16, 2021, using the search terms:
- 68 "SARS-CoV-2 seroprevalence in Africa"[Title/Abstract]) OR "SARS-CoV-2 seroprevalence in
- 69 blood donors" [Title/Abstract] OR "SARS-CoV-2 seroprevalence in Malawi", and found 15
- 70 records. There are limited SARS-CoV-2 seroprevalence studies in sub Saharan Africa,
- 71 however the few that are available report high seroprevalence than can be deduced from
- 72 the respective national reported COVID-19 cases and deaths. Only two published SARS-CoV-
- 2 serosurveys were done on blood donors, from Kenya and Madagascar. Blood donor
- serosurveys have been recommended by the WHO as an important tool for assessing the
- 75 spread of SARS-CoV-2 and estimating the burden of COVID-19 pandemic.
- 76

# 77 Added value of this study

- 78 Unlike previous SARS-CoV-2 blood donor serosurveys in African populations that were
- conducted for a maximum period of 9 months, our study covers a full year from January
- 80 2020 to February 2021, capturing potential introduction of SARS-CoV-2 into Malawi as well
- 81 as the two epidemic waves. This study provides evidence against the speculation that SARS-
- 82 CoV-2 had been circulating more widely in sub-Saharan Africa before the first detected
- 83 cases. It also provides supporting evidence suggesting that the Beta variant was the likely
- 84 driver of the second wave that resulted in high SARS-CoV-2 seropositivity in January to
- 85 February 2021 in Malawi.
- 86

# 87 Implications of all the available evidence

88 Our results show extensive community transmission of SARS-CoV-2 in Malawi as reflected in

- 89 the blood donors serosurvey, with almost half the sample population being seropositive for
- 90 anti-SARS-CoV-2 antibodies by February 2021. This has implications for COVID-19
- 91 vaccination policy in sub-Saharan Africa (SSA), where there are limited available vaccine
- 92 doses. Considering that prior exposure to SARS-CoV-2 augments COVID-19 vaccine
- 93 immunity, strategies to maximise administration of the first vaccine dose, while waiting for
- 94 more vaccines to become available, could maximise the benefits of the limited available
- 95 vaccines in high SARS-CoV-2 exposure settings in SSA such as Malawi.

# 96 Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 in 97 Hubei province, China as a cause of coronavirus disease 2019 (COVID-19)<sup>1,2</sup>. SARS-CoV-2 98 99 infection presents with a range of disease manifestations, from asymptomatic infection to 100 severe acute respiratory distress and death. SARS-CoV-2 has spread globally and the World Health Organisation (WHO) declared COVID-19 a global pandemic on 11<sup>th</sup> March 2020. As of 101 102 12th August 2021, more than 205 million people globally have been infected with more than 4.32 million deaths<sup>3</sup>. The pandemic has placed substantial pressures on health systems 103 104 delivering care for patients with COVID-19 and caused disruption of non-COVID-19 healthcare provision, in addition to negative effects on the global economy<sup>4</sup>. 105

106

107 The potential risk from SARS-CoV-2 to Africa was identified early in the global pandemic<sup>5</sup>. 108 As the epicentre of transmission moved from East Asia to West Asia, Europe and then to 109 North America, there was speculation as to the likely impact of the pandemic on the African 110 continent with its younger populations, high rates of infectious diseases including HIV, poverty and undernutrition, as well as a fragile health care infrastructure <sup>5,6</sup>. Evidence has 111 112 shown that the epidemiology of the COVID-19 pandemic in sub-Saharan Africa has been different from the Americas, China and Europe<sup>3</sup>. Available seroprevalence data indicate 113 114 that SARS-CoV-2 has circulated more widely in African populations than can be deduced from the number of reported confirmed cases, hospitalisations and deaths <sup>7-9</sup>. This has led 115 116 to speculations that SARS-CoV-2 could have circulated longer in sub-Saharan Africa than the first confirmed cases, but current evidence is limited. Others have speculated that a high 117 prevalence of circulating seasonal coronaviruses could have induced some cross-reactive 118 protective immunity <sup>10,11</sup>. 119

120

SARS-CoV-2 Spike and Nucleocapsid specific antibody responses in blood are detectable in individuals between 5 to 21 days post symptom onset <sup>12</sup>. Subsequently, anti-SARS-CoV-2 IgM antibody levels drop sharply within the initial 14 days followed by a gradual decline in anti-SARS-CoV-2 IgG antibodies within the next 6 months <sup>13</sup>, reaching undetectable levels in some individuals <sup>14</sup>. Whether these antibodies are likely to be protective against subsequent infections is becoming clearer. Anti-SARS-CoV-2 Spike antibodies generated following exposure to the original viral variant (D614G) exhibit reduced neutralisation potency against

4

the alpha and beta variants of SARS-CoV-2<sup>15-17</sup>. Conversely, antibodies generated following
 infection with the beta variant are able to potently neutralise the original variant<sup>18-20</sup>.

130

131 Though there were initial plans made by the Malawi government in April 2020 to implement a national lockdown of social and commercial activities, these were never implemented <sup>21</sup>. 132 As such, unlike other countries in the region, including Kenya<sup>22</sup>, South Africa<sup>23</sup> and 133 Zimbabwe<sup>24</sup>, there were no systematic lockdowns and limited curfew restrictions. Schools 134 were officially closed (from 23<sup>rd</sup> March 2020 to 7<sup>th</sup> September 2020) and many social 135 136 gathering settings (including restaurants and places of worship) voluntarily closed or had significantly reduced services <sup>25,26</sup>. Malawi closed its borders and airports from April 2020 to 137 September 2020, with limited essential traffic allowed in and out of the country <sup>27</sup>. As of 12<sup>th</sup> 138 139 August 2021, 56,952 people were confirmed to have been infected by SARS-CoV-2 in 140 Malawi, resulting in 1,895 deaths and 169,632 people had been fully vaccinated <sup>3</sup>. 141 Due to movement restrictions instituted to curb SARS-CoV-2 transmission, conducting large 142 143 national population-based seroprevalence studies has been a significant challenge. This has 144 led to the use of blood donor and healthcare worker serosurveys to estimate and monitor the extent of the SARS-CoV-2 pandemic in several countries <sup>7-9,28</sup>. Here, we report results of 145 a national serosurvey using archived serum samples from blood transfusion donors across 146 147 Malawi from January 2020 through February 2021, generated using a WHO-recommended 148 anti-SARS-CoV-2 Receptor Binding Domain total antibody assay with high sensitivity and 149 specificity, supported by SARS-CoV-2 pseudovirus neutralisation assays to explore variant 150 specificity.

151

# 152 Methods

# 153 Study setting and population

The Malawi Blood Transfusion Service (MBTS) maintains an archive of sera from all blood donations received in their Malawi facilities (average of 70,000 annually before the COVID-19 pandemic). All blood donors undergo routine screening through a self-administered questionnaire, one-on-one assessment and a mini-health screening by MBTS staff. Donors meeting routine donor ineligibility criteria including age below 16 or above 65 years, haemoglobin below 12.5g/dl, past medical history suggestive of HIV, hepatitis or syphilis,

160 past or present history of renal, cardiovascular, central nervous system and metabolic disorders, are excluded from donating <sup>29</sup>. All donated samples are screened for Transfusion 161 Transmissible Infections (TTI; including HIV). Sera are archived at -80°C and retained by 162 163 MBTS for up to 5 years for retrospective analysis purposes. MBTS blood donation services 164 include both static and mobile sites. For our analysis, we have selected samples from all four 165 defined regions within Malawi: Mzuzu is the capital of the Northern Region and the third 166 largest city, by population, in Malawi (population of 221,272). Lilongwe is Malawi's 167 capital city located in the Central Region (population of 989,318). Blantyre is the capital 168 of Malawi's Southern Region (population of 800,264). Balaka is a rural district of 438,379 169 residents, located in the Eastern Region. All population data are from the 2018 Malawi Population and Housing Census<sup>30</sup>. 170 171 172 Ethical approval for this study was obtained from the Kamuzu University of Health Sciences 173 Research Ethics Committee (P.09/20/3123). At time of donation, blood donors provide 174 consent to draw blood for transfusion and for use in studies of public health importance. 175 COVID-19 research qualifies as an activity of urgent public health importance.

176

# 177 Sample selection and processing

178 Using the MBTS sample archive database, we randomly selected (using STATA's gsample

179 command) sera collected from HIV-seronegative individuals aged 16-65 years old.

180 Parameters including sex, age, location and time were also extracted from the database for

181 analysis. For Mzuzu, Lilongwe and Blantyre, selected samples were only from static urban

182 donation sites. For Balaka, a largely rural district with smaller total donations, selected

183 samples included donations from both static and mobile sites, including semi-rural and

- 184 rural.
- 185

# 186 Measurement of SARS-CoV-2 antibodies by Enzyme Linked-Immunosorbent Assay

187 SARS-CoV-2 Receptor Binding Domain (RBD) Total Antibody ELISA.

- 188 We used the WHO-approved WANTAI SARS-CoV-2 Ab commercial Enzyme Linked-
- 189 Immunosorbent Assay (ELISA) kit to detect total SARS-CoV-2 antibodies, following
- 190 manufacturer's instructions (Beijing Wantai Biological Pharmacy Enterprise co., Ltd, China;
- 191 WS-1096) as reported previously<sup>31</sup>. This ELISA was shown to have the best overall

characteristics to detect functional antibodies in different phases and severity of disease <sup>31</sup>. 192 193 It is a two-step incubation antigen "sandwich" enzyme immunoassay kit which uses 194 polystyrene microwell strips pre-coated with recombinant SARS-CoV-2 Receptor Binding 195 Domain (RBD) antigen. The optical density (OD) of each well was read at 450nm in a 196 microplate reader (BioTek ELx808, UK) within 10 minutes of adding Stop Solution. Cut-off 197 values were calculated following manufacturer's instructions. The ratio between a sample's 198 absorbance and the cut-off were calculated for each sample. Specimens giving a ratio of 199 <0.9 were reported as negative for this assay, a ratio of >1.1 were reported as positive, and 200 a ratio between 0.9-1.1 were reported as borderline. Samples with borderline results were 201 retested using a confirmatory assay described below. The sensitivity and specificity of the 202 assay as independently validated are 97% [95% CI 83.3 to 99.4] and 98% [91.3 to 99.3]), 203 respectively <sup>32</sup>. The manufacturer's sensitivity and specificity estimates for the assay are 94% [90.9 to 96.8] and 100% [98.8 to 100], respectively<sup>33</sup>. 204

205

Confirmatory SARS-CoV-2 Spike 2 and Nucleoprotein IgG antibody ELISA. The COVID-19 IgG
 RUO commercial ELISA kit (Omega diagnostics, UK) kit uses 96-well microtiter plates pre coated with purified SARS-COV-2 Spike (S2) and Nucleoprotein (N) antigens to detect SARS COV-2 IgG. This was performed following manufacturer's instructions as reported
 previously<sup>7</sup>. Results were interpreted as described above for the ELISA assay, with a ratio of
 <0.9 reported as negative, a ratio of >1.1 reported as positive, and a ratio between 0.9-1.1
 reported as borderline.

213

# 214 SARS-CoV-2 Pseudovirus Neutralisation Assay

Samples were pre-screened using an in-house (NICD) spike ELISA<sup>16</sup>, and only samples 215 positive for binding antibodies were screened for neutralization. SARS-CoV-2-pseudotyped 216 lentiviruses were prepared by co-transfecting the HEK 293T cell line with either the SARS-217 218 CoV-2 original spike (D614G) or the SARS-CoV-2 Beta spike (L18F, D80A, D215G, K417N, 219 E484K, N501Y, D614G, A701V, 242-244 del) plasmids in conjunction with a firefly luciferase 220 encoding pNL4 lentivirus backbone plasmid. The parental plasmids were kindly provided by 221 Drs Elise Landais and Devin Sok (The International AIDS Vaccine Initiative (IAVI), USA). For 222 the neutralization assay, heat-inactivated seropositive serum samples from blood donors 223 were incubated with the SARS- CoV-2 pseudotyped virus for 1 hour at 37°C, 5% CO<sub>2</sub>.

- Subsequently, 1x10<sup>4</sup> HEK 293T cells engineered to over-express ACE-2, kindly provided by Dr
   Michael Farzan (Scripps Research), were added and incubated at 37°C, 5% CO<sub>2</sub> for 72 hours
   upon which the luminescence of the luciferase gene was measured.
- 227

# 228 Statistical analysis

- 229 We performed statistical analyses and graphical presentation using R statistical package,
- version 4.1.0 and GraphPad Prism v9.1.0 (GraphPad Software, LLC). The seroprevalence of
- 231 SARS-CoV-2 antibodies was adjusted for the independently reported assay sensitivity (97%
- 232 [95% CI 83.3 to 99.4]) and specificity (98% [95% CI 91.3 to 99.3]) using the bootComb
- 233 (v1.0.1) R package <sup>34</sup>. Generalised additive models were used to estimate the
- 234 seroprevalence curves from Figures 1 and 2. To investigate demographic factors associated
- with SARS-CoV-2 antibody positivity, a multivariable logistic regression model was
- 236 developed with sex, age group, location and time as predictors. To obtain smooth regression
- 237 curves, B-splines<sup>35</sup> were used to model the effect of time given the non-linear trend in
- 238 seroprevalence over time. Effects were considered statistically significant when the *p*-value
- 239 was less than 0.05.

# 240 Results

# 241 **Participant demographics**

- A total of 3,586 blood donor serum samples were selected from the four regional blood
- transfusion centres. Samples had been collected between January 2020 through February
- 244 2021. These included 823 from Mzuzu (Northern region), 946 from Lilongwe (Central
- region), 830 from Balaka (Eastern region) and 987 from Blantyre (Southern region) (**Table 1**).
- 246 Compared with 2018 Malawi Population and Housing Census<sup>30</sup>, by the nature of the
- 247 demographic of blood donors in Malawi, participants were more commonly male (75% in
- our study versus 48.5% in the census) and had more persons aged 20 to 49 years (87.3%
- 249 versus 35.4%).
- 250

# 251 Overall SARS-CoV-2 antibody seroprevalence

252 Of the 3,586 samples, 456 were positive for anti-SARS-CoV-2 RBD total antibody and 17

- 253 were borderline. After re-running the borderline samples using the separate commercial
- confirmatory ELISA, 13 of the 17 were positive for anti-SARS-CoV-2 S2 and N IgG antibody,

resulting in a total 469 anti-SARS-CoV-2 antibody positive samples (crude seroprevalence of
13.1% [95% CI 12.0% to 14.2%]).

- 257
- As part of quality control procedures, we randomly selected 76 samples that were positive
- on the primary SARS-CoV-2 ELISA and retested them using the second ELISA targeting S2
- and NP IgG. Seventy-one (71) of the 76 samples were positive on the second ELISA,
- representing a concordance of 93.4% [95% CI 85.3 to 97.8]. We also used a recently
- 262 published ELISA from the National Institute for Communicable Diseases (NICD, South
- Africa)<sup>16</sup> that targets binding antibodies against RBD of the original SARS-CoV-2 variant on a
- subset of 36 serum samples selected from the seroprevalence peaks. The concordance
- 265 between the Wantai and NICD assays was 100%.
- 266
- 267 The overall (all months aggregated) seroprevalence adjusted for the reported independent
- sensitivity and specificity estimates was 11.2% [95% CI from 5.8% to 14.9%]. In a
- 269 multivariable logistic regression model, seroprevalence did not vary significantly by sex (p =
- 270 0.532) or age (*p* > 0.10 for all age groups using those 10-19 years old as reference) but did
- vary geographically, from 5.5% in Balaka (reference) to 14.6% in Blantyre (*p* < 0.001), 9.8% in
- 272 Lilongwe (*p* < 0.001) and 14.6% in Mzuzu (*p* < 0.001) (**Table 2**).
- 273

# 274 **Temporal trend of SARS-CoV-2 seroprevalence**

275 The first PCR-confirmed case of COVID-19 identified by Malawi's national surveillance system was on 2<sup>nd</sup> April 2021, with the first peak of the national COVID-19 cases being July 276 277 2020 (2,813 cases) and subsequently a second peak in January 2021 (17,380 cases) (Figure 278 1). In this blood donor SARS-CoV-2 serosurvey, the first seropositive samples were observed 279 in February 2020 in Balaka (1 sample) and March 2020 in Blantyre (2 samples) (Figure 2, 280 Table 3 and Supplementary Table 1). Both unadjusted and adjusted seroprevalence 281 estimates increased with time, with two distinct waves that followed the same temporal 282 trend as the reported national COVID-19 cases (Figure 1 and Supplementary Table 1). When 283 aggregating serum samples from all locations, the first wave among donors was observed 284 from July to November 2020 with the peak seroprevalence in October 2020 (15.7% adjusted 285 seroprevalence), while the second wave was observed between December 2020 to February 286 2021 with peak seroprevalence in February 2021 (49.4%) (Figure 1, Table 3 and

287 **Supplementary Table 1**). However, there were differences in the temporal trend in seroprevalence according to location (Figure 2, Table 3 and Supplementary Table 1). Balaka 288 289 had a 0% adjusted seroprevalence from January to November 2020, subsequently increasing 290 from 1.9% to 37.5% between December 2020 and February 2021. The peak adjusted 291 seroprevalence in the first wave was July 2020 in the Blantyre (15.9%), August 2020 in 292 Lilongwe (13.1%) and October 2020 in Mzuzu (24.8%). Seroprevalence bubble plots at three 293 periods in time demonstrated widespread exposure amongst blood donors across the 294 country in February 2021 compared to the earlier snapshots (Figure 3).

295

# 296 Estimating predominant SARS-CoV-2 variants driving seroprevalence

297 Limited evidence suggests that Malawi's second wave was driven by the Beta variant, with 298 data deposited on GISAID showing that the variant was identified in 96% (152/159) of the samples sequenced from Malawi from January 2021<sup>36</sup>. As it has been shown that antibodies 299 elicited by the original variant (D614G WT) are less potent against the Beta variant<sup>16,19</sup>, we 300 301 reasoned that differential neutralisation potency by SARS-CoV-2 antibodies could be used to 302 estimate the predominance of specific variants driving seroprevalence. We therefore 303 measured neutralisation antibody responses against D614G WT and Beta variant in 304 randomly selected seropositive sera collected at the peak of the first wave (Wave 1) in June 305 to October 2020 compared to those collected in February 2021 (Wave 2). Wave 1 sera was 306 more potent against D614G WT than the Beta variant, while Wave 2 sera was relatively 307 more potent against the Beta variant than D614G WT (Figure 4a-b). Only 22% (2/9) of the 308 Wave 1 sera was more potent against the Beta variant than D614G WT, while 47% 8/17 of 309 the Wave 2 sera was more potent against the Beta variant than D614G WT (Figure 4b-c). In 310 contrast, 78% (7/9) of the Wave 1 sera was more potent against D614G WT than the Beta 311 variant, while 18% 3/17 of the Wave 2 sera was more potent against D614G WT than the 312 Beta variant (Figure 4c). Furthermore, 35% (6/17) of the Wave 2 sera showed no 313 neutralisation against the Beta variant or D614G WT (Figure 4c). Collectively, these results 314 support existing sequencing evidence that Malawi's second SARS-CoV-2 epidemic wave was 315 driven by the Beta variant. 316

- 317
- 318

# 319 Discussion

Our study provides important insights into the dynamics of the COVID-19 epidemic in both 320 urban and rural Malawi, with likely relevance to the southern Africa region. The 321 322 seroprevalence estimates from this blood donor serosurvey are very high compared to the 323 reported national surveillance figures for confirmed asymptomatic and symptomatic cases, 324 but they do reflect the emergence and magnitude of the first and second COVID-19 325 epidemic waves in Malawi. They also provide evidence against the speculation that SARS-326 CoV-2 had been circulating more widely in Malawi before the first detected case in April 2020 or that circulation of endemic coronaviruses <sup>10,11</sup> had generated cross-reactive 327 328 antibody responses. Data from pseudovirus neutralisation assays suggests that the second 329 wave was predominantly driven by the Beta variant, as sera from the first wave had poor 330 neutralising activity against the Beta variant of SARS-CoV-2. Collectively, our findings 331 provide further support to the emerging data that in terms of hospitalised disease and 332 death, the COVID-19 pandemic has so far been attenuated in sub-Saharan Africa, despite 333 high population exposure to SARS-CoV-2.

334

335 We report a high seroprevalence of 49.7% nationally in February 2021, mirroring the 336 upsurge in confirmed COVID-19 cases, hospitalisations and death in Malawi experienced during this period <sup>3,6</sup>. This is consistent with a study in South African blood donors that 337 reported seroprevalence rates ranging from 31.8% to 62.5% in January 2021 <sup>37</sup>. So far, the 338 339 epidemic trajectory in Malawi as determined by the national confirmed COVID-19 cases, deaths and hospitalisations has paralleled the epidemic trajectory in South Africa<sup>3</sup>. This is 340 341 likely due to shared borders and the resulting frequent human migration between the two countries, specifically in the last 12 months during which there has been an influx of groups 342 343 of returning residents from South Africa to Malawi. This movement of people coincided with rapid surges in COVID-19 cases in the first and second epidemic waves in Malawi<sup>38</sup>. These 344 345 findings support the need for a consolidated and standardised regional public health effort 346 in effectively addressing the COVID-19 pandemic in southern Africa to reduce the risk of 347 further epidemic waves across the region.

348

Genomic surveillance data from Malawi and South Africa suggests that this high
 seroprevalence in the second wave is, at least in part, driven by the emergence of the Beta

variant <sup>36</sup>. In agreement, our neutralisation data showed that sera collected from the second 351 352 wave (February 2021) was better at neutralising the Beta variant than that from the first wave (June to October 2020), indicating antibody responses driven by infection with the 353 354 Beta variant rather than the original variant (D614G WT). This is consistent with previous 355 studies showing that homologous convalescent sera retain higher *in vitro* neutralisation potency than heterogous convalescent sera against the infecting virus <sup>15-20</sup>. It is noteworthy 356 357 that 35% of the Wave two sera that were positive for antibodies to the SARS-CoV-2 RBD 358 showed no neutralisation against the Beta variant or D614G WT, highlighting a disconnect 359 between qualitative antibody detection and functional activity. This discordance could be 360 due to low anti-RBD antibody titers as they have been shown to be associated with poor in vitro neutratisalion <sup>19,20</sup>. 361

362

363 The temporal kinetics of the SARS-CoV-2 seroprevalence in this blood donor serosurvey 364 suggests that the first epidemic wave was largely confined to urban areas. This differs to the 365 second wave, which was not only more rapid in its growth but also in its geographic spread, 366 as shown by the high seroprevalence even in the rural areas. This is consistent with national surveillance reports showing that confirmed COVID-19 cases in the first wave were primarily 367 368 from the three major cities, Blantyre, Lilongwe and Mzuzu, but in the second wave there was an increase in reported cases in rural areas <sup>39,40</sup>. Also noteworthy is the earlier 369 370 seroprevalence peak in Blantyre and Lilongwe, compared to the northern city of Mzuzu. 371 Blantyre and Lilongwe are the largest commercial centres in Malawi with multiple 372 connection to South Africa through international airports and bus stations. Mzuzu is the hub 373 for inter-country trade and migration between Tanzania and Malawi and it is plausible that 374 some of the late epidemic surge in Mzuzu was due to cross border movement of persons 375 between Tanzania and Malawi.

376

This study has considerable strengths, including consistent monthly sampling, use of wellvalidated assays and national geographical representation. There are however some important limitations. First, inherent in using a blood donor sampling frame is that the convenience sampling was not representative of the general population, skewed towards males and individuals aged 18 to 45 years old. In addition, we were unable to evaluate the association between the behaviour of blood donors and risk of acquisition to SARS-CoV-2

12

383 infection, as this may bias the measured results away from the true population 384 seropositivity. Though random sampling from the larger population would have been ideal, restrictions on movement and gathering make these study designs extremely challenging to 385 386 implement. Second, in some individuals, SARS-CoV-2 antibodies wane over time to 387 undetectable levels leading to false negatives, especially in those who had asymptomatic COVID-19<sup>12-14</sup>. Therefore, the seroprevalence estimates are likely an underestimate of the 388 389 cumulative exposure within this sampled population. However, the selection bias and 390 waning of antibody levels is unlikely to substantially alter the temporal trends reported in 391 this study.

392

393 In conclusion, we report a dramatic rise in SARS-CoV-2 seroprevalence from 6.2% in July 394 2020 to 49.7% in February 2021 in healthy blood donors as Malawi experienced the first and 395 second COVID-19 epidemic waves, likely driven initially by the original variant (D614G WT) 396 and then the Beta variant. Based on data showing prior exposure to SARS-CoV-2 augments COVID-19 vaccine responses <sup>41-44</sup>, prioritisation of the first COVID-19 vaccine dose in settings 397 398 with high seroprevalence could help maximise the benefit of the limited available COVID-19 399 vaccine doses. The dynamics of SARS-CoV-2 exposure will therefore need to be taken into 400 account in the formulation of COVID-19 vaccination policy in Malawi and across the region.

401

# 402 Acknowledgements

403 The authors thank all blood donors whose samples are used in this study, the staff of the

404 Malawi-Liverpool-Wellcome Trust Clinical Research Programme (MLW) and Malawi Blood

405 Transfusion Services (MBTS) for their support and co-operation during the study.

406

# 407 Author Contributions

408 KCJ, TDS, RSH, NF, BM, TM, AM and NK designed the study. KCJ, TDS, TM, GK, AL, NM and
409 PLM supervised the work. JM, CB, AS, FA, ZM, TM, NM, AS and TMG processed all samples
410 and carried out all laboratory-based assays. MYRH, BM and JM carried out data

- 411 management and statistical analysis. KCJ, TDS, JM, RSH and NF wrote the initial manuscript
- 412 draft. All authors reviewed and approved the final manuscript.
- 413
- 414

# 415 Funding

- 416 This research was funded by the National Institute for Health Research (NIHR) (16/136/46)
- 417 using UK aid from the UK Government to support global health research. K.C.J. is supported
- 418 by an MRC African Research Leader award [MR/T008822/1]. RSH is a NIHR Senior
- 419 Investigator. The views expressed in this publication are those of the author(s) and not
- 420 necessarily those of the NIHR or the UK government. P.L.M. is supported by the South
- 421 African Research Chairs Initiative of the Department of Science and Innovation and the
- 422 National Research Foundation (Grant No 98341) and the MRC Strategic Health Innovations
- 423 Program of the SA MRC. A Wellcome Strategic award number 206545/Z/17/Z supports the
- 424 Malawi-Liverpool-Wellcome Trust Clinical Research Programme. The Malawi Blood
- 425 Transfusion Service is funded by the Government of Malawi and development partners.
- 426

# 427 **Declaration of Interests**

- 428 The authors declare no competing interests.
- 429

# 430 **References**

Coronaviridae Study Group of the International Committee on Taxonomy of V. The
 species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and
 naming it SARS-CoV-2. *Nat Microbiol* 2020; 5(4): 536-44.

434 2. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global
435 health concern. *Lancet* 2020; **395**(10223): 470-3.

436 3. JHU. COVID-19 Case Tracker 2020. <u>https://coronavirus.jhu.edu/map.html</u>.

437 4. Kaye AD, Okeagu CN, Pham AD, et al. Economic impact of COVID-19 pandemic on
438 healthcare facilities and systems: International perspectives. *Best Pract Res Clin Anaesthesiol*439 2020.

440 5. Walker PGT, Whittaker C, Watson OJ, et al. The impact of COVID-19 and strategies
441 for mitigation and suppression in low- and middle-income countries. *Science* 2020.

442 6. Morton B, Barnes KG, Anscombe C, et al. Distinct clinical and immunological profiles

443 of patients with evidence of SARS-CoV-2 infection in sub-Saharan Africa. *Nat Commun* 2021;
444 **12**(1): 3554.

Chibwana M, Jere K, Kamng'ona R, et al. High SARS-CoV-2 seroprevalence in health
care workers but relatively low numbers of deaths in urban Malawi [version 2; peer review:
2 approved]. *Wellcome Open Research* 2020; 5(199).

8. Olayanju O, Bamidele O, Edem F, et al. SARS-CoV-2 Seropositivity in Asymptomatic
Frontline Health Workers in Ibadan, Nigeria. *The American journal of tropical medicine and hygiene* 2021; **104**(1): 91-4.

451 9. Uyoga S, Adetifa IMO, Karanja HK, et al. Seroprevalence of anti-SARS-CoV-2 lgG
452 antibodies in Kenyan blood donors. *Science* 2021; **371**(6524): 79-82.

453 10. Peterson I, Bar-Zeev N, Kennedy N, et al. Respiratory Virus-Associated Severe Acute

454 Respiratory Illness and Viral Clustering in Malawian Children in a Setting With a High

455 Prevalence of HIV Infection, Malaria, and Malnutrition. *J Infect Dis* 2016; **214**(11): 1700-11.

456 11. Ho A, Mallewa J, Peterson I, et al. Epidemiology of Severe Acute Respiratory Illness

457 and Risk Factors for Influenza Infection and Clinical Severity among Adults in Malawi, 2011-

458 2013. The American journal of tropical medicine and hygiene 2018; **99**(3): 772-9.

Huang AT, Garcia-Carreras B, Hitchings MDT, et al. A systematic review of antibody
mediated immunity to coronaviruses: kinetics, correlates of protection, and association with
severity. *Nat Commun* 2020; **11**(1): 4704.

462 13. Anand SP, Prevost J, Nayrac M, et al. Longitudinal analysis of humoral immunity
463 against SARS-CoV-2 Spike in convalescent individuals up to eight months post-symptom
464 onset. *Cell Rep Med* 2021: 100290.

465 14. den Hartog G, Vos ERA, van den Hoogen LL, et al. Persistence of antibodies to SARS466 CoV-2 in relation to symptoms in a nationwide prospective study. *Clinical Infectious Diseases*467 2021.

Xie X, Liu Y, Liu J, et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and
N501Y variants by BNT162b2 vaccine-elicited sera. *Nature Medicine* 2021; **27**(4): 620-1.

470 16. Wibmer CK, Ayres F, Hermanus T, et al. SARS-CoV-2 501Y.V2 escapes neutralization

471 by South African COVID-19 donor plasma. *Nature Medicine* 2021; **27**(4): 622-5.

472 17. Supasa P, Zhou D, Dejnirattisai W, et al. Reduced neutralization of SARS-CoV-2

473 B.1.1.7 variant by convalescent and vaccine sera. *Cell* 2021; **184**(8): 2201-11.e7.

474 18. Cele S, Gazy I, Jackson L, et al. Escape of SARS-CoV-2 501Y.V2 from neutralization by

475 convalescent plasma. *Nature* 2021; **593**(7857): 142-6.

- 476 19. Moyo-Gwete T, Madzivhandila M, Makhado Z, et al. SARS-CoV-2 501Y.V2 (B.1.351)
- 477 elicits cross-reactive neutralizing antibodies. *bioRxiv* 2021: 2021.03.06.434193.
- 478 20. Dupont L, Snell LB, Graham C, et al. Antibody longevity and cross-neutralizing activity
- 479 following SARS-CoV-2 wave 1 and B.1.1.7 infections. *medRxiv* 2021: 2021.06.07.21258351.
- 480 21. Masina L. Judge in Malawi Blocks Government Lockdown, at Least Temporarily.
- 481 2020. <u>https://www.voanews.com/covid-19-pandemic/judge-malawi-blocks-government-</u>
- 482 <u>lockdown-least-temporarily</u>.
- 483 22. Star R. Uhuru unlikely to lift curfew, lockdown as Covid-19 cases rise. 2020.
- 484 https://www.the-star.co.ke/news/2020-06-05-uhuru-unlikely-to-lift-curfew-lockdown-as-
- 485 <u>covid-19-cases-rise/</u>.
- 486 23. Government SA. President Ramaphosa announces a nationwide lockdown. 2020-03-
- 487 23 2020. https://www.sanews.gov.za/south-africa/president-ramaphosa-announces-
- 488 <u>nationwide-lockdown</u>.
- 489 24. Mavhunga C. Zimbabwe Begins Lockdown to Fight COVID19. 2020.
- 490 <u>https://www.voanews.com/science-health/coronavirus-outbreak/zimbabwe-begins-</u>
- 491 <u>lockdown-fight-covid19</u>.
- 492 25. Kondowe R. Why a country with no coronavirus cases has declared a national
- 493 disaster and shut schools. 2020. <u>https://qz.com/africa/1824465/coronavirus-malawi-with-</u>
- 494 <u>no-cases-declares-national-disaster/</u>.
- 495 26. Masina L. Malawi President Announces Plans to Reopen Schools in September. 2020.
- 496 <u>https://www.voanews.com/covid-19-pandemic/malawi-president-announces-plans-reopen-</u>
- 497 <u>schools-september</u>.
- 498 27. Cocks T. Malawi to lift Covid-19 international air travel restrictions from September.
- 499 2020. https://www.businesslive.co.za/bd/world/africa/2020-08-27-malawi-to-lift-covid-19-
- 500 international-air-travel-restrictions-from-september/.
- 501 28. Rusakaniko S, Sibanda EN, Mduluza T, et al. SARS-CoV-2 Serological testing in
- 502 frontline health workers in Zimbabwe. *PLOS Neglected Tropical Diseases* 2021; **15**(3):
- 503 e0009254.
- 504 29. M'Baya B, Jumbe V, Samuel V, M'Bwana R, Mangani C. Seroprevalence and trends in
- 505 transfusion transmissible infections among voluntary non-remunerated blood donors at the
- 506 Malawi Blood Transfusion Service-a time trend study. *Malawi medical journal : the journal*
- 507 *of Medical Association of Malawi* 2019; **31**(2): 118-25.

- 508 30. NSO. Malawi Population and Housing Census. Zomba: National Statistical Office,
- 509 Malawi, 2018.
- 510 31. GeurtsvanKessel CH, Okba NMA, Igloi Z, et al. An evaluation of COVID-19 serological
- 511 assays informs future diagnostics and exposure assessment. *Nature Communications* 2020;
- 512 **11**(1): 3436.
- 513 32. Wantai. WANTAI SARS-CoV-2 Ab ELISA 2021.
- 514 https://www.fda.gov/media/140929/download.
- 515 33. Wantai. WANTAI SARS-CoV-2 Ab ELISA. 2021.
- 516 https://www.bioscience.co.uk/resources/sars-cov-2-ab-elisa-ifu.pdf.
- 517 34. Henrion MYR. bootComb—an R package to derive confidence intervals for
- 518 combinations of independent parameter estimates. *International Journal of Epidemiology*
- 519 2021.
- 520 35. Talebitooti R, Shojaeefard MH, Yarmohammadisatri S. Shape design optimization of
- 521 cylindrical tank using b-spline curves. *Computers & Fluids* 2015; **109**: 100-12.
- 522 36. Wilkinson E, Giovanetti M, Tegally H, et al. A year of genomic surveillance reveals
- 523 how the SARS-CoV-2 pandemic unfolded in Africa. *medRxiv* 2021: 2021.05.12.21257080.
- 524 37. Sykes W, Mhlanga L, Swanevelder R, et al. Prevalence of anti-SARS-CoV-2 antibodies
- among blood donors in Northern Cape, KwaZulu-Natal, Eastern Cape, and Free State
- 526 provinces of South Africa in January 2021. *Res Sq* 2021: rs.3.rs-233375.
- 527 38. Masina L. 2021. <u>https://www.voanews.com/covid-19-pandemic/malawi-mandates-</u>
  528 guarantine-returnees-south-africa.
- 529 39. Government M. COVID-19 MOH MALAWI. 2021. https://covid19.health.gov.mw/.
- 530 40. Ngwira A, Kumwenda F, Munthali ECS, Nkolokosa D. Spatial temporal distribution of
- 531 COVID-19 risk during the early phase of the pandemic in Malawi. *PeerJ* 2021; **9**: e11003.
- 532 41. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Protection afforded by the
- 533 BNT162b2 and mRNA-1273 COVID-19 vaccines in fully vaccinated cohorts with and without
- 534 prior infection. *medRxiv* 2021: 2021.07.25.21261093.
- 535 42. Havervall S, Marking U, Greilert-Norin N, et al. Antibody Responses After a Single
- 536 Dose of ChAdOx1 nCoV-19 Vaccine in Healthcare Workers Previously Infected with SARS-
- 537 CoV-2. *medRxiv* 2021: 2021.05.08.21256866.

538	43.	Wei J, Stoesser N, Matthews PC, et al. Antibody responses to SARS-CoV-2 vaccines in
539	45,965	adults from the general population of the United Kingdom. Nature Microbiology
540	2021.	
541	44.	Manisty C, Otter AD, Treibel TA, et al. Antibody response to first BNT162b2 dose in
542	previou	usly SARS-CoV-2-infected individuals. The Lancet 2021; <b>397</b> (10279): 1057-8.
543		
544		
545		
546		
547		
548		
549		
550		
551		
552		
553		
554		
555		
556		
557		
558		
559		
560		
561		
562		
563		
564		
565		
566		
567		
568		
569		

### **Tables**

## Table 1. Participant Demographics and site characteristics

	Balaka	Blantyre	Lilongwe	Mzuzu	Total
Region	Eastern	Southern	Central	Northern	
Rural/urban	Rural	Urban	Urban	Urban	
Pop density (persons/km <sup>2</sup> ) <sup>φ</sup>	205	3334	2455	1516	
Sampling frame	All locations	Static	Static	Static	
Gender, % male (N)	74.2% (616)	78.1% (771)	64.1% (606)	84.1% (692)	74.9% (2685)
Age, median (IQR)	20.9 (20.0-25.9)	26.9 (21.9-33.4)	29.8 (22.8-38.2)	25.8 (21.2-33.6)	25.7 (20.8-34.0)
Sample size	830	987	946	823	3586

<sup>®</sup>Source 2018 Malawi Population and Housing Census main report; IQR=interquartile range; Km=kilometre

## Table 2. SARS-CoV-2 anti-RBD total antibody seroprevalence in blood donors by

## participant characteristics and location

579 580

## This a multivariable logistic regression model with sex, age group, location and time as predictors. B-splines were used to model the effect of time given the non-linear trend in seroprevalence over time.

Variable	Category	Sample	Seropositive	Unadjusted	Adjusted				
		size	(frequency)	Seroprevalence	Seroprevalence				
				(%)	(%)	Estimate	SE	z value	p value
Intercept						-14.731	2.213	-6.658	P<0.001
Gender	Female	901	108	12.0	9.5	Ref	Ref	Ref	Ref
	Male	2685	361	13.4	11.0	-0.083	0.133	-0.625	0.532
Age	10 - 19 <sup>§</sup>	420	35	8.3	5.6	Ref	Ref	Ref	Ref
	20 - 29	1844	246	13.3	10.8	0.198	0.181	1.099	0.272
	30 - 39	798	112	14.0	11.6	0.215	0.201	1.067	0.286
	40 - 49	487	72	14.8	12.4	0.322	0.216	1.490	0.136
	50+	37	4	10.8	8.2	-0.577	1.050	-0.549	0.583
Location	Balaka	830	64	7.7	5.5	Ref	Ref	Ref	Ref
	Blantyre	987	160	16.2	14.6	1.005	0.177	5.684	<0.001*
	Lilongwe	946	111	11.7	9.8	0.704	0.187	3.765	<0.001*
	Mzuzu	823	134	16.3	14.6	1.187	0.183	6.496	<0.001*

582 § Recruitment limited to blood donors ≥16 years of age

\* Significant based on p-value < 0.05

## Table 3. Adjusted seroprevalence, stratified by month and site

Yr-month	Balaka % (95% CI)	Blantyre % (95% Cl)	Lilongwe % (95% CI)	Mzuzu % (95% Cl)	Total % (95% Cl)
2020-01	0.0 (0.0, 4.7)	0.0 (0.0, 6.6)	0.0 (0.0, 6.7)	0.0 (0.0, 5.2)	0.0 (0.0, 2.4)
2020-02	0.0 (0.0, 9.5)	0.0 (0.0, 6.6)	0.0 (0.0, 7.9)	0.0 (0.0, 6.4)	0.0 (0.0, 2.8)
2020-03	0.0 (0.0, 6.8)	1.5 (0.0, 11.1)	0.0 (0.0, 6.7)	0.0 (0.0, 7.1)	0.0 (0.0, 2.8)
2020-04	0.0 (0.0, 7.0)	0.0 (0.0, 7.1)	0.0 (0.0, 6.8)	0.0 (0.0, 8.6)	0.0 (0.0, 2.8)
2020-05	0.0 (0.0, 9.5)	0.0 (0.0, 6.1)	0.2 (0.0, 12.5)	1.3 (0.0, 10.4)	0.0 (0.0, 3.9)
2020-06	0.0 (0.0, 6.2)	0.0 (0.0, 9.6)	0.0 (0.0, 5.4)	0.0 (0.0, 8.8)	0.0 (0.0, 2.7)
2020-07	0.0 (0.0, 6.2)	15.9 (2.9, 31.2)	7.3 (0.0, 16.4)	6.6 (0.0, 17.6)	6.2 (0.5, 11.4)
2020-08	0.0 (0.0, 6.7)	14.7 (3.3, 27.6)	13.1 (2.2, 25.6)	13.7 (0.0, 40.9)	8.4 (1.7, 14.4)
2020-09	0.0 (0.0, 4.7)	14.6 (4.8, 25.0)	7.2 (0.1, 14.5)	18.2 (6.6, 31.3)	9.4 (3.0, 14.9)
2020-10	0.0 (0.0, 10.8)	16.7 (7.0, 26.8)	8.1 (0.2, 16.5)	24.8 (14.8, 35.2)	15.7 (8.9, 22.0)
2020-11	0.6 (0.0, 8.7)	15.6 (6.0, 25.9)	13.9 (5.4, 22.6)	6.8 (0.0, 14.7)	10.4 (4.0, 15.8)
2020-12	1.9 (0.0, 12.0)	11.0 (2.5, 19.8)	6.0 (0.0, 16.5)	13.4 (3.1, 25.0)	9.1 (2.7, 14.9)
2021-01	23.9 (9.4, 40.2)	23.2 (13.2, 33.7)	18.8 (8.8, 29.7)	34.7 (19.9, 50.7)	24.0 (16.7, 31.2)
2021-02	37.5 (26.7, 49.0)	54.8 (42.4, 67.5)	54.5 (39.8, 70.4)	57.5 (44.4, 72.1)	49.7 (42.3 <i>,</i> 58.8)



medRxiv preprint doi: https://doi.org/10.1101/2021.08.18.21262207; this version posted August 22, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .



Figure 2. Flexible seroprevalence models. The model fits provide a smoothed estimate of the seroprevalence over time (January 2020 to February 2021) for each location: Blantyre, Lilongwe, Balaka, and Mzuzu. The orange line is the line of best fit for the empirical data, using a smooth generalised additive model, along with light-orange shading indicating 95% CI. Black dots (together with 95% CI) are estimated seroprevalence at each timepoint (month), adjusted for assay sensitivity and specificity. Grey dots (a top and bottom of figures) show the individual-level data, which are either positive (1) or negative (0) for detection of anti- SARS-CoV-2 receptor binding domain (RBD) antibody. 







705

